Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber
Study Details
Study Description
Brief Summary
This is a prospective, single center, non-comparative, 90-day follow-up, post-market clinical investigation of etacoat in patients undergoing cataract surgery.
The performance is evaluated by the preservation of endothelial cells measured by specular microscopy at the follow-up visit in comparison to baseline values.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Specular microscopy to measure the preservation of endothelium [90 days post surgery compared to baseline]
Secondary Outcome Measures
- Specular microscopy to measure the corneal thickness [post surgery, 1 day and 90 days post surgery compared to baseline]
- Intraocular pressure measurement [post surgery, 1 day and 90 days post surgery compared to baseline]
- Questionnaire to assess the satisfaction with the application [day 0]
Questionnaire contains the subjective evaluation by the investigator of the IMD's rheological properties as well as the maintenance of the patient's anterior chamber and dome. Scale for the chamber and dome maintenance ranges from flat (worst case) to full chamber (best case) maintained. Scale for rheological properties ranges from dispersive (best case) to cohesive (worst case).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients indicated for cataract surgery via the anterior chamber
-
A negative urine pregnany test at Visit 1 or 2
-
Capability to understand information about the investigation, including patients' obligations, and willingness to take part, as evidenced by signed and dated informed consent.
Exclusion Criteria:
-
Patient who are known to be hypersensitive to HPMC or other components of the device
-
Patients with corneal scars or corneal dystrophies interfering with study measurements
-
Abnormal intraocular pressure which would interfere with surgery and follow up (in opinion of the investigator)
-
Any other condition that in the opinion of the investigator would interfere with the participation in this investigation
-
Any person dependent on the investigator or employees of the investigation site institution or the Sponsor
-
Current or previous (within 30 days of enrollment) treatment with another investigational drug and/or medical device or participation in another clinical study
-
Patients whose participation in clinical trials is prohibited by the Austrian Medical Devices Act
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital | Vienna | Austria |
Sponsors and Collaborators
- Croma-Pharma GmbH
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CPH-401-201287